Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 5/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.42 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3334926 | 0.88 | KDM4E (0.49) | ALDH1A1LMNASMN1; SMN2USP2TSHR | |
| SCHEMBL3333745 | 0.87 | PANK3 (0.39) | MAPTKMT2AMEN1HTT | |
| SCHEMBL3338988 | 0.75 | KDM4E (0.52) | ALDH1A1SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL8170099 | 0.75 | ALDH1A1 (0.42) | ALDH1A1LMNASMN1; SMN2USP2TSHR | |
| SCHEMBL3333658 | 0.74 | ME2 (0.48) | SMN1; SMN2MAPTL3MBTL1 | |
| SCHEMBL3338768 | 0.72 | MEN1 (0.50) | ALDH1A1SMN1; SMN2MAPTL3MBTL1KMT2A | |
| SCHEMBL3333697 | 0.68 | MAPT (0.46) | ALDH1A1SMN1; SMN2TSHRMAPTKMT2A | |
| SCHEMBL3334649 | 0.67 | KDM4E (0.62) | ALDH1A1SMN1; SMN2MAPTKMT2AMEN1 | |
| SCHEMBL8170094 | 0.67 | KDM4E (0.40) | MAPTKMT2AMEN1HTT | |
| SCHEMBL3334891 | 0.67 | KDM4E (0.53) | ALDH1A1SMN1; SMN2MAPTL3MBTL1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | claimed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | ALDH1A1 1506/4885LMNA 4343/4885SMN1; SMN2 913/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.